Drug intelligence / Profile preview

BL-030

Development stage: Preclinical
Lead developer: Bilayer Therapeutics
Modality: Small Molecules

Overview

BL-030 is a small molecule drug initially developed by Bilayer Therapeutics. It is being investigated for the treatment of digestive system disorders, with its primary active indication being ulcerative colitis. As of March 2025, the drug remains in preclinical development and has not yet advanced to clinical trials or received regulatory approval. Detailed information about its mechanism of action, molecular targets, or specific pharmacological properties has not been disclosed publicly[1].

Beyond the preview

Go deeper on BL-030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-030.

Explore the full profile